Patents by Inventor Alexander Ploss

Alexander Ploss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220362276
    Abstract: Provided herein are methods involving a compound of the following structural formula: (I) or a pharmaceutically acceptable salt thereof, wherein values for the variables are as described herein. For example, methods for inhibiting replication of a virus, treating a viral infection, inhibiting heat shock protein 90 and treating a heat shock protein 90-mediated disease or condition using a compound of Structural Formula I are provided.
    Type: Application
    Filed: May 12, 2020
    Publication date: November 17, 2022
    Inventors: Alexander Ploss, Ila Nimgaonkar, Hahn Kim
  • Patent number: 10883980
    Abstract: The present invention provides a method of inhibiting hepatitis E virus (HEV) release from a cell that is infected with an HEV, and a method of treating a HEV infection in a subject in need thereof. The present invention also provides a method of identifying agent that inhibits HEV infectivity using a transcomplementation system.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: January 5, 2021
    Assignee: The Trustees of Princeton University
    Inventors: Alexander Ploss, Qiang Ding
  • Publication number: 20190204297
    Abstract: The present invention provides a method of inhibiting hepatitis E virus (HEV) release from a cell that is infected with an HEV, and a method of treating a HEV infection in a subject in need thereof. The present invention also provides a method of identifying agent that inhibits HEV infectivity using a transcomplementation system.
    Type: Application
    Filed: September 21, 2017
    Publication date: July 4, 2019
    Inventors: Alexander Ploss, Qiang Ding
  • Patent number: 8940960
    Abstract: The human Occludin protein is identified as an essential Hepatitis C Virus (HCV) cell entry factor. Occludin is shown to render murine and other non-human cells infectable with HCV and to be required for HCV-susceptibility of human cells. Associated methods for inhibiting HCV infection, transgenic animal models for HCV pathogenesis, methods of identifying compounds or agents that prevent or mitigate interaction of HCV with Occludin, and HCV inhibitory agents are also disclosed. Kits and cell culture compositions useful for identifying compounds or agents that prevent or mitigate interaction of HCV with Occludin are also provided.
    Type: Grant
    Filed: October 1, 2009
    Date of Patent: January 27, 2015
    Assignee: The Rockefeller University
    Inventors: Alexander Ploss, Matthew Evans, Charles Rice
  • Publication number: 20110318730
    Abstract: Cell cultures are provided that include a population of micropatterened hepatocytes and one or more non-parenchymal cell populations, where the hepatocytes are infected with a virus or parasite and include a reporter of virus or parasite infection. Methods of making and using the cell cultures are also provided.
    Type: Application
    Filed: July 7, 2009
    Publication date: December 29, 2011
    Applicants: THE ROCKEFELLER UNIVERSITY, MASS INSTITUTE OF TECHNOLOGY
    Inventors: Charles M. Rice, III, Christopher Thomas Jones, Alexander Ploss, Sangeeta N. Bhatia, Salman Khetani
  • Publication number: 20110271356
    Abstract: The human Occludin protein is identified as an essential Hepatitis C Virus (HCV) cell entry factor. Occludin is shown to render murine and other non-human cells infectable with HCV and to be required for HCV—susceptibility of human cells. Associated methods for inhibiting HCV infection, transgenic animal models for HCV pathogenesis, methods of identifying compounds or agents that prevent or mitigate interaction of HCV with Occludin, and HCV inhibitory agents are also disclosed. Kits and cell culture compositions useful for identifying compounds or agents that prevent or mitigate interaction of HCV with Occludin are also provided.
    Type: Application
    Filed: October 1, 2009
    Publication date: November 3, 2011
    Applicant: THE ROCKEFELLER UNIVERSITY
    Inventors: Alexander Ploss, Matthew Evans, Charles Rice